394 related articles for article (PubMed ID: 27088632)
1. Treatment of Helicobacter pylori infection: Where are we now?
Liou JM; Wu MS; Lin JT
J Gastroenterol Hepatol; 2016 Dec; 31(12):1918-1926. PubMed ID: 27088632
[TBL] [Abstract][Full Text] [Related]
2. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
3. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.
Miftahussurur M; Yamaoka Y
Molecules; 2015 Apr; 20(4):6068-92. PubMed ID: 25856059
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori eradication in West Asia: a review.
Fakheri H; Bari Z; Aarabi M; Malekzadeh R
World J Gastroenterol; 2014 Aug; 20(30):10355-67. PubMed ID: 25132752
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.
Dos Santos AA; Carvalho AA
World J Gastroenterol; 2015 Jan; 21(1):139-54. PubMed ID: 25574087
[TBL] [Abstract][Full Text] [Related]
6. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.
Papastergiou V; Georgopoulos SD; Karatapanis S
World J Gastroenterol; 2014 Aug; 20(29):9898-911. PubMed ID: 25110420
[TBL] [Abstract][Full Text] [Related]
8. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era.
Georgopoulos SD; Papastergiou V; Karatapanis S
Expert Opin Pharmacother; 2015; 16(15):2307-17. PubMed ID: 26330278
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Helicobacter pylori infection 2016.
O'Connor A; Fischbach W; Gisbert JP; O'Morain C
Helicobacter; 2016 Sep; 21 Suppl 1():55-61. PubMed ID: 27531541
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
[TBL] [Abstract][Full Text] [Related]
13. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Helicobacter; 2016 Oct; 21(5):382-8. PubMed ID: 26809022
[TBL] [Abstract][Full Text] [Related]
14. Toward population specific and personalized treatment of Helicobacter pylori infection.
Liou JM; Chen PY; Kuo YT; Wu MS;
J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori.
Malfertheiner P; Selgrad M
Curr Opin Gastroenterol; 2014 Nov; 30(6):589-95. PubMed ID: 25268839
[TBL] [Abstract][Full Text] [Related]
16. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
[TBL] [Abstract][Full Text] [Related]
17. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Marin AC; McNicholl AG; Gisbert JP
Expert Opin Pharmacother; 2013 May; 14(7):843-61. PubMed ID: 23537368
[TBL] [Abstract][Full Text] [Related]
18. Practical Aspects in Choosing a Helicobacter pylori Therapy.
Molina-Infante J; Shiotani A
Gastroenterol Clin North Am; 2015 Sep; 44(3):519-35. PubMed ID: 26314666
[TBL] [Abstract][Full Text] [Related]
19. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities.
Kawai T; Yamagishi T; Yagi K; Kataoka M; Kawakami K; Sofuni A; Itoi T; Sakai Y; Moriyasu F; Osaka Y; Takagi Y; Aoki T; Rimbara E; Noguchi N; Sasatsu M
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S171-4. PubMed ID: 19120893
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
